Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance

This publication has 39 references indexed in Scilit:

• Cetuximab (C), fluorouracil (F), and cisplatin (P) alone or with docetaxel (D) for recurrent/metastatic (RM) head and neck cancer (HNSCC): First analysis of AIO trial # 1108.
  Journal of Clinical Oncology, 2014
• Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck
  European Journal of Cancer, 2013
• Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes
  Oral Oncology, 2013
• Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
  Annals of Oncology, 2012
• Current Treatment Options for Metastatic Head and Neck Cancer
  Current Treatment Options in Oncology, 2012
• Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
  Annals of Oncology, 2011
• Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  Annals of Oncology, 2010
• Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
  New England Journal of Medicine, 2008
• Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study
  Journal of Clinical Oncology, 2005
• Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group
  Journal of Clinical Oncology, 2005